SCHEMBL27002080

SCHEMBL27002080

COc1cc(/C=C/[N+](=O)[O-])cc(OC)c1SCCC(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VCP P55072 5/20 0.51
▸ MAPT P10636 4/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ LMNA P02545 3/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ HTT P42858 3/20 0.48
▸ EGFR P00533 2/20 0.48
▸ SYK P43405 2/20 0.48
▸ GALR2 O43603 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ ABL1 P00519 1/20 0.42
▸ ABL2 P42684 1/20 0.42
▸ FBP1 P09467 4/20 0.41
▸ HSP90AA1 P07900 3/20 0.39
▸ AGTR1 P30556 1/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27125943 1.00 VCP (0.51) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27002197 0.93 VCP (0.49) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27137697 0.93 VCP (0.49) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27002028 0.83 VCP (0.52) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27129122 0.83 VCP (0.52) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27140006 0.82 VCP (0.51) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27002145 0.82 VCP (0.51) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27002037 0.81 VCP (0.50) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27128757 0.81 VCP (0.50) VCPMAPTALDH1A1LMNAMAPK1
SCHEMBL27002026 0.79 AR (0.43) MAPTALDH1A1LMNAMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166618-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME GILGAMESH PHARMACEUTICALS, INC. (US) 2024-05-23 — — US disclosed
CN-117642379-A Phenylalkylamines and methods of making and using the same 吉尔伽美什制药公司 2024-03-01 — — CN disclosed
EP-4305019-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME Gilgamesh Pharmaceuticals, Inc. (US) 2024-01-17 — — EP disclosed
WO-2022192781-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME GILGAMESH PHARMACEUTICALS, INC. (US) 2022-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166618-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME PNMT, HTR6, HTR2C VCP 1420/4885MAPT 596/4885ALDH1A1 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback